Structure-based antivirals for emerging and neglected RNA viruses: An emerging field for medicinal chemistry in academia

Future Medicinal Chemistry

Volumn 2, Issue 7, 2010, Pages 1061-1067

  Hilgenfeld, Rolf ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; PEPTIDIC ALDEHYDE DERIVATIVE; PROTEINASE; PROTEINASE INHIBITOR; RUPINTRIVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CHEMICAL ANALYSIS; CLINICAL TRIAL; DEVELOPED COUNTRY; DRUG DESIGN; DRUG INDUSTRY; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; EPIDEMIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL RESEARCH; NONHUMAN; NOTE; PRIORITY JOURNAL; RNA VIRUS; VIRUS INFECTION;

ANIMALS; ANTIVIRAL AGENTS; CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS AS TOPIC; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; DRUG DESIGN; HUMANS; ISOXAZOLES; PROTEASE INHIBITORS; PYRROLIDINONES; RNA VIRUS INFECTIONS; RNA VIRUSES;

EID: 77954685784     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.10.211     Document Type: Note

References (53)

1. Broder S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res. 85, 1-18 (2010).
2. DeClercq E. Antiviral therapy: quo vadis? Future Med. Chem. 2(7), 1049-1053 (2010)
3. Abstracts of the 23rd International Conference on Antivirals, San Francisco, CA, 25-28 April, 2010. Antiviral Res. 86, A1-A76 (2010).
4. Ojima I. Medicinal chemistry at a crossroads: challenges and new possibilities. Future Med. Chem. 1, 401-403 (2009).
5. Raveglia LF, Giardina GAM. Accelarating the drug-discovery process: new tools and technologies available to medicinal chemists. Future Med. Chem. 1(6), 1019-1023 (2009).
6. Wyatt PG. The emerging academic drug-discovery sector. Future Med. Chem. 1(6), 1013-1017 (2009).
7. Wlodawer A, Miller M, Jaskolski M et al. Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science 245, 616-621 (1989).
8. Blundell TL, Lapatto R, Wilderspin AF et al. The 3D structure of HIV-1 proteinase and the design of antiviral agents for the treatment of AIDS. Trends Biochem. Sci. 15, 425-430 (1990).
9. Navia MA, Fitzgerald PM, McKeever BM et al. 3D structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature 337, 615-620 (1989).
10. Vondrasek J, Wlodawer A. HIVdb: a database of the structures of human immunodeficiency virus protease. Proteins 49, 429-431 (2002).
11. Lee CC, Kuo CJ, Ko TP et al. Structural basis of inhibition specificities of 3C and 3C-like proteases by zinc-coordinating and peptidomimetic compounds. J. Biol. Chem. 284, 7646-7655 (2009).
12. Steuber H, Hilgenfeld R. Recent advances in targeting viral proteases for the discovery of novel antivirals. Curr. Top. Med. Chem. 23, 323-345 (2010).
13. De Palma AM, Vliegen I, De Clercq E, Neyts J. Selective inhibitors of picornavirus replication. Med. Res. Rev. 28, 823-884 (2008).
14. Matthews DA, Dragovich PS, Webber SE et al. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc. Natl Acad. Sci. USA 96, 11000-11007 (1999).
15. Johnson TO, Hua Y, Luu HT et al. Structure-based design of a parallel synthetic array directed toward the discovery of irreversible inhibitors of human rhinovirus 3C protease. J. Med. Chem. 45, 2016-2023 (2002).
16. Binford SL, Maldonade F, Brothers MA et al. Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor. Antimicrob. Agents Chemother. 49, 619-626 (2005).
17. Patick AK. Rhinovirus chemotherapy. Antiviral Res. 71, 391-396 (2006).
18. Sawyer MH. Enterovirus infections, diagnosis and treatment. Semin. Pediatr. Infect. Dis. 13, 40-47 (2002).
19. Yang F, Ren L, Xiong Z et al. Enterovirus 71 outbreak in the People's Republic of China in 2008. J. Clin. Microbiol. 47, 2351-2352 (2009).
20. Zhang Y, Tan XJ, Wang HY et al. An outbreak of hand, foot, and mouth disease associated with subgenotype C4 of human enterovirus 71 in Shandong, China. J. Clin. Virol. 44, 262-267 (2009).
21. Coutard B, Gorbalenya AE, Snijder EJ et al. The VIZIER project: preparedness against pathogenic RNA viruses. Antiviral Res. 78, 37-46 (2008).
22. Matthews DA, Smith WW, Ferre RA et al. Structure of human rhinovirus 3C protease reveals a trypsin-like polypeptide fold, RNA-binding site, and means for cleaving precursor polyprotein. Cell 77, 761-777 (1994).
23. Schechter I, Berger A. On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. 27, 157-162 (1967).
24. Lee ES, Lee WG, Yun SH et al. Development of potent inhibitors of the Coxsackievirus 3C protease. Biochem. Biophys. Res. Commun. 358, 7-11 (2007).
25. Kuo CJ, Shie JJ, Fang JM et al. Design, synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents. Bioorg. Med. Chem. 16, 7388-7398 (2008).
26. Anand K, Palm GJ, Mesters JR, Siddell SG, Ziebuhr J, Hilgenfeld R. Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra a-helical domain. EMBO J. 21, 3213-3224 (2002).
27. Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of antiSARS drugs. Science 300, 1763-1767 (2003).
28. Yang H, Yang M, Ding Y et al. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc. Natl Acad. Sci. USA 100, 13190-13195 (2003).
29. Yang H, Xie W, Xue X et al. Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLoSBiol. 3, 1742-1752 (2005).
30. Wu CY, King KY, Kuo CJ et al. Stable benzotriazole esters as mechanism-based inactivators of the severe acute respiratory syndrome 3CL protease. Chem. Biol. 13, 261-268 (2006).
31. Verschueren KHG, Pumpor K, Anemuller S, Chen S, Mesters JR, Hilgenfeld R. A structural view of the inactivation of the SARS-coronavirus main proteinase by benzotriazole esters. Chem. Biol. 15, 597-606 (2008).
32. Al Gharabli SI, Shah ST, Weik S et al. An efficient method for the synthesis of peptide aldehyde libraries employed in the discovery of reversible SARS coronavirus main protease (SARS-CoV Mpro) inhibitors. ChemBioChem 7, 1048-1055 (2006).
33. Schmidt MF, Isidro-Llobet A, Lisurek M et al. Sensitized detection of inhibitory fragments and iterative development of nonpeptidic protease inhibitors by dynamic ligation screening. Angew. Chem. Int. Ed. Engl. 47, 3275-3278 (2008).
34. Chen S, Jonas F, Shen C, Hilgenfeld R. Liberation of SARS-CoV main protease from the viral polyprotein: N-terminal autocleavage does not depend on the mature dimerization mode. Protein Cell, 1, 59-74 (2010).
35. Zhang S, Zhong N, Xue F et al. 3D domain swapping as a mechanism to lock the active conformation in a super-active octamer of SARS-CoV main protease. Protein Cell, 1, 371-383 (2010).
36. Lisurek M, Rupp B, Wichard J et al. Design of chemical libraries with potentially bioactive molecules applying a maximum common substructure concept. Mol. Divers. 14, 401-408 (2010).
37. Ratia K, Pegan S, Takayama J et al. A noncovalent class of papain-like protease/ deubiquitinase inhibitors blocks SARS virus replication. Proc. Natl Acad. Sci. USA 105, 16119-16124 (2008).
38. Lau SK, Li KS, Huang Y et al. Ecoepidemiology and complete genome comparison of different strains of severe acute respiratory syndrome-related Rhinolophus bat coronavirus in China reveal bats as a reservoir for acute, self-limiting infection that allows recombination events. J. Virol. 84, 2808-2819 (2010).
39. Yuan J, Hon CC, Li Y et al. Intraspecies diversity of SARS-like coronaviruses in Rhinolophus sinicus and its implications for the origin of SARS coronaviruses in humans. J. Gen. Virol. 91, 1058-1062 (2010).
40. Pfefferle S, Oppong S, Drexler JF et al. Distant relatives of severe acute respiratory syndrome coronavirus and close relatives of human coronavirus 229E in bats, Ghana. Emerg. Infect. Dis. 15, 1377-1384 (2009).
41. Rihtaric D, Hostnik P, Steyer A, Grom J, Toplak I. Identification of SARS-like coronaviruses in horseshoe bats (Rhinolophus hipposideros) in Slovenia. Arch. Virol. 155, 507-514 (2010).
42. Gloza-Rausch F, Ipsen A, Seebens A et al. Detection and prevalence patterns of group I coronaviruses in bats, Northern Germany. Emerg. Infect. Dis. 14, 626-631 (2008).
43. van der Hoek L, Pyrc K, Jebbink MF et al. Identification of a new human coronavirus. Nature Med. 10, 368-373 (2004).
44. Woo PC, Lau SK, Chu CM et al. Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. J. Virol. 79, 884-895 (2005).
45. Collett MS, Neyts J, Modlin JF. A case for developing antiviral drugs against polio. Antiviral Res. 79, 179-187 (2008).
46. Jiang P, Faase JAJ, Toyoda H, Paul A, Wimmer E, Gorbalenya AE. Evidence for emergence of diverse polioviruses from C-cluster Coxsackie A viruses and implications for global poliovirus eradication. Proc. Natl Acad. Sci. USA 104, 9457-9462 (2007).
47. Rakoto-Andrianarivelo M, Guillot S, Iber J et al. Co-circulation and evolution of polioviruses and species C enteroviruses in a district of Madagascar. PloS Pathogens 3, 1950-1961 (2007).
48. Couzin J. Report concludes polio drugs are needed after disease is eradicated. Science 311, 1539 (2006).
49. De Palma AM, Puerstinger G, Wimmer E et al. Comparative activity of a selected series of antipicornavirus compounds against poliovirus replication in vitro. Emerg. Infect. Dis. 14, 545-551 (2008).
50. VIZIER Project www.vizier-europe.org
51. Global polio eradication initiative. Programme of Work 2009 and financial resource requirements 2009-2013, as of May 2009 WHO, Rotary International, CDC, Unicef. www.polioeradication.org/content/general/ Final-English. GPEIProgrammeofWork2009. pdf
52. World Health Organisation Country Office Tajikistan, WHO Regional Office for Europe, European Centre for Disease Prevention and Control. Outbreak of poliomyelitis in Tajikistan in 2010: risk for importation and impact on polio surveillance in Europe? Eurosurveillance, 15, issue 17, April 29, 2010 www.eurosurveillance.org/Public/Articles/ Archives.aspx
53. International Consortium om Antivirals www.icav-citav.org